In a single-center case series to evaluate the efficacy and safety of high-dose upadacitinib (Rinvoq) for the treatment of inpatients with acute severe ulcerative colitis (UC) or severe Crohn's ...
Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients on upadacitinib 15 mg and 30 mg achieved clinical remission (40.4% and 53.6%) ...
In two phase 3 induction trials (U-EXCEL and U-EXCEED), we randomly assigned patients with moderate-to-severe Crohn’s disease to receive 45 mg of upadacitinib or placebo (2:1 ratio) once daily for 12 ...
Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback